AU2002333644A1
(en)
|
2001-09-17 |
2003-04-01 |
Glaxo Group Limited |
Dry powder medicament formulations
|
US6653323B2
(en)
|
2001-11-13 |
2003-11-25 |
Theravance, Inc. |
Aryl aniline β2 adrenergic receptor agonists
|
TWI249515B
(en)
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
EP1507754A1
(en)
*
|
2002-05-28 |
2005-02-23 |
Theravance, Inc. |
Alkoxy aryl beta-2 adrenergic receptor agonists
|
AR040661A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Theravance Inc |
Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
|
US6844362B2
(en)
|
2002-10-11 |
2005-01-18 |
Pfizer Inc |
Indole derivatives useful for the treatment of diseases
|
JP2006528242A
(ja)
|
2003-05-08 |
2006-12-14 |
セラヴァンス インコーポレーテッド |
アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態
|
TW200510277A
(en)
*
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
US7375100B2
(en)
|
2003-06-04 |
2008-05-20 |
Pfizer Inc |
2-amino-pyridine derivatives useful for the treatment of diseases
|
US7067541B2
(en)
|
2003-06-04 |
2006-06-27 |
Pfizer Inc |
2-amino-pyridine derivatives useful for the treatment of diseases
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
CA2534985A1
(en)
|
2003-08-11 |
2005-02-24 |
Glaxo Group Limited |
Pharmaceutical metered dose inhaler and methods relating thereto
|
TW200526547A
(en)
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
TW200531692A
(en)
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
CA2553293C
(en)
|
2004-01-22 |
2010-12-14 |
Pfizer Inc. |
Sulfonamide derivatives for the treatment of diseases
|
EP1577291A1
(en)
*
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamine derivatives as beta-2 agonists
|
AU2005223488A1
(en)
*
|
2004-03-17 |
2005-09-29 |
Pfizer Inc. |
Phenylethanolamine derivatives as Beta-2 agonists
|
BRPI0507877A
(pt)
*
|
2004-03-23 |
2007-07-24 |
Pfizer |
derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
|
GB0425054D0
(en)
*
|
2004-03-23 |
2004-12-15 |
Pfizer Ltd |
Formamide derivatives for the treatment of diseases
|
CA2561400A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
US20080039495A1
(en)
|
2004-06-03 |
2008-02-14 |
Linsell Martin S |
Diamine Beta2 Adrenergic Receptor Agonists
|
EP1778638A1
(en)
|
2004-07-21 |
2007-05-02 |
Theravance, Inc. |
Diaryl ether beta2 adrenergic receptor agonists
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
WO2006066907A1
(en)
*
|
2004-12-21 |
2006-06-29 |
Glaxo Group Limited |
Pharmaceutical formulations
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
BRPI0614290A2
(pt)
|
2005-08-08 |
2011-03-22 |
Argenta Discovery Ltd |
derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
AR058104A1
(es)
|
2005-10-21 |
2008-01-23 |
Novartis Ag |
Compuestos organicos
|
AR058109A1
(es)
|
2005-12-20 |
2008-01-23 |
Glaxo Group Ltd |
Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
TW200745084A
(en)
*
|
2006-03-08 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
TW200745067A
(en)
|
2006-03-14 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
EA200801997A1
(ru)
|
2006-04-20 |
2009-04-28 |
Глаксо Груп Лимитед |
Новые соединения
|
JP5373599B2
(ja)
|
2006-04-21 |
2013-12-18 |
ノバルティス アーゲー |
アデノシンa2a受容体アゴニストとして使用するためのプリン誘導体
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
AR061571A1
(es)
|
2006-06-23 |
2008-09-03 |
Smithkline Beecham Corp |
Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
|
ES2302447B1
(es)
*
|
2006-10-20 |
2009-06-12 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
TW200833670A
(en)
|
2006-12-20 |
2008-08-16 |
Astrazeneca Ab |
Novel compounds 569
|
BRPI0720799A2
(pt)
|
2007-01-10 |
2014-03-11 |
Irm Llc |
Compostos e composições como inibidores de protease de ativação de canal.
|
GB0702458D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
Salts 668
|
EA200901082A1
(ru)
|
2007-02-09 |
2010-02-26 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
|
ES2306595B1
(es)
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
AU2008248598B2
(en)
|
2007-05-07 |
2011-11-17 |
Novartis Ag |
Organic compounds
|
ES2320961B1
(es)
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
CA2707857C
(en)
|
2007-12-10 |
2016-09-13 |
Novartis Ag |
Spirocyclic amiloride analogues
|
WO2009087224A1
(en)
|
2008-01-11 |
2009-07-16 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
JP5791500B2
(ja)
|
2008-05-23 |
2015-10-07 |
パンミラ ファーマシューティカルズ,エルエルシー. |
5−リポキシゲナーゼ活性化タンパク質阻害剤
|
WO2009147187A1
(en)
|
2008-06-05 |
2009-12-10 |
Glaxo Group Limited |
4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
CA2726746A1
(en)
|
2008-06-18 |
2009-12-23 |
Astrazeneca Ab |
Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
DK2379507T3
(da)
|
2008-12-30 |
2014-01-27 |
Pulmagen Therapeutics Inflammation Ltd |
Sulfonamidforbindelser til behandling af åndedrætsforstyrrelser
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
WO2010102958A1
(en)
|
2009-03-09 |
2010-09-16 |
Glaxo Group Limited |
4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
WO2010106016A1
(en)
|
2009-03-17 |
2010-09-23 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
MX2011010072A
(es)
|
2009-03-27 |
2011-10-06 |
Merck Sharp & Dohme |
Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
WO2010122089A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as crac channel inhibitors
|
ME02900B
(me)
|
2009-04-30 |
2018-04-20 |
Glaxo Group Ltd |
Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
AU2010310449A1
(en)
|
2009-10-22 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
JP2013512879A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体
|
EP2507226A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Novel compounds
|
JP2013512880A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3−キナーゼ阻害剤としてのインダゾール誘導体
|
US20120272951A1
(en)
|
2009-12-16 |
2012-11-01 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
WO2012032546A2
(en)
*
|
2010-09-08 |
2012-03-15 |
Cadila Healthcare Limited |
Process for the preparation of salmeterol and its intermediates
|
PT2614058E
(pt)
|
2010-09-08 |
2015-10-27 |
Glaxosmithkline Ip Dev Ltd |
Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
EP2630127A1
(en)
|
2010-10-21 |
2013-08-28 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
ES2532213T3
(es)
|
2010-10-21 |
2015-03-25 |
Glaxo Group Limited |
Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
GEP20156285B
(en)
|
2011-02-25 |
2015-05-11 |
Aierem Elelsi |
Compounds and compositions as trk inhibitors
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
JP2014507458A
(ja)
|
2011-03-11 |
2014-03-27 |
グラクソ グループ リミテッド |
Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
US9034879B2
(en)
|
2011-09-16 |
2015-05-19 |
Novartis Ag |
Heterocyclic compounds for the treatment of CF
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
EP2647627A1
(en)
*
|
2012-04-02 |
2013-10-09 |
Almirall, S.A. |
Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
JP6475707B2
(ja)
|
2013-10-17 |
2019-02-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
呼吸器疾患の治療のためのpi3k阻害剤
|
EP3057587A1
(en)
|
2013-10-17 |
2016-08-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
JP6454727B2
(ja)
|
2014-04-24 |
2019-01-16 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピリジン誘導体
|
EP3134397A1
(en)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
BR112016023967A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
|
PE20170185A1
(es)
|
2014-05-12 |
2017-04-01 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones farmaceuticas para tratar enfermedades infecciosas
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3497100A1
(en)
|
2016-08-08 |
2019-06-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
BR112021024668A2
(pt)
|
2019-06-10 |
2022-05-31 |
Novartis Ag |
Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
|
JOP20220044A1
(ar)
|
2019-08-28 |
2023-01-30 |
Novartis Ag |
مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|